Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric B Haura

Showing results (111-120 of 201) with videos related to

Pageof 21
Sort By:
Plos One|July 1, 2021
Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancerDung-Tsa Chen, Wenyaw Chan, Zachary J Thompson, et al.
JCO Clinical Cancer Informatics|September 12, 2025
Using Bayesian Networks to Predict Urgent Care Visits in Patients Receiving Systemic Therapy for Non-Small Cell Lung CancerBrian D Gonzalez, Xiaoyin Li, Lisa M Gudenkauf, et al.
Journal of Proteome Research|November 18, 2010
Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivityGuolin Zhang, Bin Fang, Richard Z Liu, et al.
Cancer Research|October 29, 2014
Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutationsYun Bai, Jae-Young Kim, January M Watters, et al.
Molecular & Cellular Proteomics : MCP|September 16, 2018
Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer CellsClaudia Ctortecka, Vinayak Palve, Brent M Kuenzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2021
Cell Type-specific Adaptive Signaling Responses to KRAS<sup>G12C</sup> InhibitionHitendra S Solanki, Eric A Welsh, Bin Fang, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2014
TGF-β-inducible microRNA-183 silences tumor-associated natural killer cellsSarah S Donatelli, Jun-Min Zhou, Danielle L Gilvary, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Trastuzumab Deruxtecan Combination Strongly Enhances Responses and Overcomes Sotorasib Resistance in <i>KRAS</i> <sup>G12C</sup> -Mutant NSCLCHilal Ozakinci, Bina Desai, Denise Kalos, et al.
Translational Lung Cancer Research|May 22, 2026
Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in <i>KRAS<sup>G12C</sup></i> -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumorsHilal Ozakinci, Bina Desai, Denise Kalos, et al.
Journal of Thoracic Disease|December 13, 2023
Osimertinib <i>vs.</i> afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an <i>EGFR</i> exon 19 deletion or exon 21 L858R mutationSophia Gilardone, Ram Thapa, José Laborde, et al.
Pageof 21

Showing results (111-120 of 201) with videos related to

Sort By:
Pageof 21
Plos One|July 1, 2021
Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancerDung-Tsa Chen, Wenyaw Chan, Zachary J Thompson, et al.
JCO Clinical Cancer Informatics|September 12, 2025
Using Bayesian Networks to Predict Urgent Care Visits in Patients Receiving Systemic Therapy for Non-Small Cell Lung CancerBrian D Gonzalez, Xiaoyin Li, Lisa M Gudenkauf, et al.
Journal of Proteome Research|November 18, 2010
Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivityGuolin Zhang, Bin Fang, Richard Z Liu, et al.
Cancer Research|October 29, 2014
Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutationsYun Bai, Jae-Young Kim, January M Watters, et al.
Molecular & Cellular Proteomics : MCP|September 16, 2018
Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer CellsClaudia Ctortecka, Vinayak Palve, Brent M Kuenzi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2021
Cell Type-specific Adaptive Signaling Responses to KRAS<sup>G12C</sup> InhibitionHitendra S Solanki, Eric A Welsh, Bin Fang, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2014
TGF-β-inducible microRNA-183 silences tumor-associated natural killer cellsSarah S Donatelli, Jun-Min Zhou, Danielle L Gilvary, et al.
Biorxiv : the Preprint Server for Biology|January 7, 2025
Trastuzumab Deruxtecan Combination Strongly Enhances Responses and Overcomes Sotorasib Resistance in <i>KRAS</i> <sup>G12C</sup> -Mutant NSCLCHilal Ozakinci, Bina Desai, Denise Kalos, et al.
Translational Lung Cancer Research|May 22, 2026
Pre-clinical efficacy of trastuzumab deruxtecan plus sotorasib in <i>KRAS<sup>G12C</sup></i> -mutant non-small cell lung cancer and exploratory HER2 profiling in human tumorsHilal Ozakinci, Bina Desai, Denise Kalos, et al.
Journal of Thoracic Disease|December 13, 2023
Osimertinib <i>vs.</i> afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an <i>EGFR</i> exon 19 deletion or exon 21 L858R mutationSophia Gilardone, Ram Thapa, José Laborde, et al.
Pageof 21